SEC Form 4 · accession 0001628280-26-043987
Acumen Pharmaceuticals, Inc. · ABOS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Derrell Porter
Director
Period of report
Jun 15, 2026
Accepted (ET)
Jun 17, 2026 · 5:10 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001576885
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 15, 2026 | M | 6,460 | $1.07 | A | 54,760 | D | |
| Common Stock | Jun 15, 2026 | S | 6,460 | $2.345 | D | 48,300 | D | |
| Common StockF1 | Jun 16, 2026 | S | 12,800 | $2.326 | D | 35,500 | D | |
| Common Stock | Jun 17, 2026 | M | 13,040 | $1.07 | A | 48,540 | D | |
| Common Stock | Jun 17, 2026 | S | 13,040 | $2.325 | D | 35,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $1.07 | Jun 15, 2026 | M | 6,460 | D | — | Jun 4, 2035 | Common Stock | 6,460 | 13,040 | D |
| Stock Option (right to buy)F2 | $1.07 | Jun 17, 2026 | M | 13,040 | D | — | Jun 4, 2035 | Common Stock | 13,040 | 0 | D |
Explanation of responses
- F1The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.305 to $2.345. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2The shares subject to the option vested in full on the date of the 2026 annual stockholder meeting.